A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells

Cell Stem Cell. 2022 Mar 3;29(3):434-448.e5. doi: 10.1016/j.stem.2022.01.013. Epub 2022 Feb 17.

Abstract

Midbrain dopamine (mDA) neurons can be replaced in patients with Parkinson's disease (PD) in order to provide long-term improvement in motor functions. The limited capacity for long-distance axonal growth in the adult brain means that cells are transplanted ectopically, into the striatal target. As a consequence, several mDA pathways are not re-instated, which may underlie the incomplete restoration of motor function in patients. Here, we show that viral delivery of GDNF to the striatum, in conjunction with homotopic transplantation of human pluripotent stem-cell-derived mDA neurons, recapitulates brain-wide mDA target innervation. The grafts provided re-instatement of striatal dopamine levels and correction of motor function and also connectivity with additional mDA target nuclei not well innervated by ectopic grafts. These results demonstrate the remarkable capacity for achieving functional and anatomically precise reconstruction of long-distance circuitry in the adult brain by matching appropriate growth-factor signaling to grafting of specific cell types.

Keywords: GDNF; PITX3; Parkinson’s disease; axon growth; cell therapy; neural transplantation; neurotrophic; regeneration; retrograde tracing; substantia nigra.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Dopamine* / metabolism
  • Genetic Therapy
  • Glial Cell Line-Derived Neurotrophic Factor / metabolism
  • Humans
  • Mesencephalon / metabolism
  • Pluripotent Stem Cells* / metabolism
  • Substantia Nigra / metabolism
  • Substantia Nigra / transplantation

Substances

  • Glial Cell Line-Derived Neurotrophic Factor
  • Dopamine